New lupus drug safety under scrutiny in taiwan
NCT ID NCT04645589
Summary
This study observed 72 patients in Taiwan with lupus nephritis (kidney inflammation from lupus) who were newly prescribed Myfortic. The main goal was to monitor the drug's safety and side effects over 12 months of routine use. Researchers also tracked whether patients' kidney function improved or stabilized.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Kaohsiung City, 83301, Taiwan
-
Novartis Investigative Site
Keelung, 20401, Taiwan
-
Novartis Investigative Site
Taichung, 407219, Taiwan
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
Novartis Investigative Site
Taipei, 105, Taiwan
-
Novartis Investigative Site
Taoyuan District, 33305, Taiwan
Conditions
Explore the condition pages connected to this study.